{"prompt": "['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', 'Observation period', 'The TEAE observation period is defined as the time from the first dose of IMP up to', '7 days after the last dose of IMP.', 'The on-study period is defined as the time from randomization until the end of the study', '(see definition in Section 6.2.1).', '11.4.3.1 Adverse events', 'Treatment-emergent AEs, treatment-emergent SAEs, TEAEs leading to treatment discontinuation', 'and treatment-emergent AESIs will be summarized for each treatment group based on MedDRA', 'coding of verbatim terms reported by investigators.', 'Analysis of TEAEs', 'Treatment emergent adverse event incidence tables will be presented by system organ class (SOC)', '(sorted by internationally agreed order), high-level group term (HLGT), high level term (HLT)', 'and preferred term (PT), sorted in alphabetical order for each treatment group, the number (n) and', 'percentage (%) of patients experiencing at least one TEAE. Multiple occurrences of the same', 'event in the same patient will be counted only once in the tables within a treatment phase. The', 'denominator for computation of percentages is the safety population within each treatment group.', 'Analysis of all treatment-emergent SAEs', 'All treatment-emergent SAEs will be presented by primary SOC, HLGT, HLT, and PT, showing', 'number (%) of patients with at least 1 serious TEAE, sorted by SOC internationally agreed order.', 'The order levels (HLGT, HLT, PT) will be presented in alphabetical order. Listings will be', 'provided for all SAEs by treatment group and patient with flags indicating on-treatment status.', 'Analysis of all TEAEs leading to permanent treatment discontinuation', 'TEAEs leading to treatment discontinuation will be presented by primary SOC, HLGT, HLT, and', 'PT, showing number (%) of patients with at least 1 TEAE leading to permanent treatment', 'discontinuation, sorted by SOC internationally agreed order. The order levels (HLGT, HLT, PT)', 'will be presented in alphabetical order. Listings will be provided for all TEAE leading to', 'permanent treatment discontinuation by treatment group and patient.', 'Analysis of treatment-emergent AESI:', 'Treatment-emergent AESI, by AESI category and PT, will show number (%) of patients overall,', 'sorted by decreasing incidence of PT within each AESI category. The AESIs include, but are not', 'limited to, the following categories and details of the MedDRA coding will be provided in the', 'SAP: (see AESI list in Section 10.4.1.3): AESIs include hypotension/orthostatic hypotension', 'symptomatic or not.', 'Property of the Sanofi Group - strictly confidential', 'Page 81', '(electronic 4.0)']['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', 'Analysis of Deaths', 'The following deaths summaries will be generated:', 'Number (%) of patients who died by study period (TEAE, on-study) and reasons for death', 'summarized on the safety population by treatment received.', 'Death in nonrandomized patients or randomized and not treated patients.', 'TEAE leading to death (death as an outcome on the AE CRF page as reported by the', 'Investigator) by primary SOC, HLGT, HLT and PT showing number (%) of patients', 'sorted by internationally agreed order of SOC and alphabetic order of HLGT, HLT, and', 'PT.', '11.4.3.2 Laboratory data', 'The summary statistics (including number, mean, median, Q1, Q3, standard deviation, minimum', 'and maximum) of all laboratory variables will be calculated for each visit or study assessment', '(baseline, each post-baseline time point, endpoint) by treatment group. Listings will be provided', 'with flags indicating the out of range values as well as the PCSA values.', 'The incidence of PCSA at any time will be summarized by treatment group for each laboratory', 'parameter. Shift tables showing changes with respect to the baseline status will be provided.', '11.4.3.3 Potential drug-induced liver injury', 'The liver function tests, namely ALT, AST, alkaline phosphatase, and total bilirubin, are used to', 'assess possible drug-induced liver toxicity. The proportion of patients with PCSA values at any', 'post-baseline visit by baseline status will be displayed by treatment group for each parameter. The', 'proportion of patients with PCSA values at any post-baseline visit will also be displayed by', 'duration of exposure for each treatment group.', 'A graph of distribution of peak values of ALT versus peak values of total bilirubin will also be', 'presented. Note that the ALT and total bilirubin values are presented on a logarithmic scale. The', 'graph will be divided into 4 quadrants with a vertical line corresponding to 3 X ULN for ALT and', 'a horizontal line corresponding to 2 X ULN for total bilirubin.', 'The normalization (to 1 x ULN or return to baseline if baseline >ULN) of elevated liver function', 'tests will be summarized by categories of elevation (3 X ULN, 5 X ULN, 10 X ULN, 20 X ULN for', 'ALT and AST; 1.5 X ULN for alkaline phosphatase; and 1.5 X ULN and 2 X ULN for total', 'bilirubin), with the following categories of normalization: never normalized, normalized after', 'permanent discontinuation of study drug. Note that a patient will be counted only under the', 'maximum elevation category.', 'The incidence of liver-related AEs will be summarized by treatment group. The selection of', 'preferred terms will be based on standardized MedDRA query (SMQ) Hepatic disorder.', 'Property of the Sanofi Group - strictly confidential', 'Page 82', '(electronic 4.0)']\n\n###\n\n", "completion": "END"}